Novartis Investigative Site

Summary

Novartis Investigative Site is a medical facility located in TORONTO, Ontario. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Melanoma, Pancreatic Cancer and other specialties. Novartis Investigative Site is involved with conducting 222 clinical trials across 243 conditions. There are 0 research doctors associated with this hospital, such as .

Top PIs

Clinical Trials running at Novartis Investigative Site

Breast Cancer

Follicular Lymphoma

Breast cancer

Prostate Cancer

Carcinoid Tumor

Relapse

Acute Lymphoblastic Leukemia

Pancreatic Cancer

Colorectal Cancer

Lung Cancer

Ribociclib + Hormone Therapy

for Breast Cancer

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).

Recruiting

2 awards

Phase 3

4 criteria

[177Lu]Lu-NeoB + Capecitabine

for Metastatic Breast Cancer

In the phase I part, to determine the recommended doses (RD) and dosing regimens of \[177Lu\]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor. In the phase II part, to evaluate the preliminary anti-tumor activity of two different doses/regimens of \[177Lu\]Lu-NeoB in combination with capecitabine (dose optimization).

Recruiting

1 award

Phase 1 & 2

5 criteria

Radioactive Drugs

for Breast Cancer

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).

Recruiting

1 award

Phase 1

5 criteria